RESOURCES

/

FIND A SPECIALIST

/

CONTACT

The FDA Needs to Hear Your Voice

The FDA is currently reviewing a potential treatment for focal segmental glomerulosclerosis (FSGS). Sign our letter to the FDA to ensure that the lived experiences of patients and caregivers are part of this decision. Your journey with FSGS matters. Your voice matters. And right now, it matters more than ever that you are heard. Sign NephCure's letter to the FDA by 2/18. 

Sign now

Rachel Slattery

Director, Events Strategy

Rachel Slattery serves as the Associate Director of Development for NephCure. Before joining the team in May 2019, she started her career in the event planning industry at the Chamber of Commerce for Greater Philadelphia and has experience coordinating small to large scale events of all types from start to finish. Rachel is passionate about turning events into unforgettable experiences and helping others along the way. In her spare time, she loves to travel, hike and spend time with her Maltipoo dog, Peanut!

King of Prussia, PA

Related News

NEWS

Letter to the NephCure Community: Update on FDA Decision About Sparsentan for FSGS

NEWS

NephCure Unveils New Mission Focusing on New Era of Access for Rare Kidney Disease Patients

NEWS

The FDA Grants Accelerated Approval to VOYXACT, a New Treatment Option for Adults with IgA Nephropathy

NEWS

NephCure Wins Silver at the Fifth Annual Anthem Awards for Kidney Month Campaign

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.